WTA's new one-time gene test: the headline, the how, and why everyone's talking

Okay, so the WTA just dropped a rule that’s going to be sticking in headlines for a while: every player on the women’s tour must now take a one-time genetic sex test focused on the SRY gene, and a negative result is required to compete. This isn't a tiny tweak — it’s a major eligibility shift, and it takes effect from this Tuesday.

What did the WTA actually announce?

Short version: mandatory one-time test, samples can be a cheek swab, blood, or saliva, and a negative SRY result is needed to play on tour.

• One-time test for a player's whole career — the WTA says you only have to give a sample once.
• What they’re testing for — the presence of the SRY gene, which is tied to Y-chromosome-driven male sex development. The BBC explains the science angle and the sample options.
• If you test positive — the WTA says there will be further medical assessment before they make any eligibility decision.
• Refusing to test — players will have to sign an acknowledgement that refusal could lead to disciplinary action.
• When it starts — the policy is effective from Tuesday onward, per the WTA announcement covered in ESPN.

Those are the nuts and bolts. The WTA framed this as a women’s eligibility rule “based on biological sex” and tied the timing to broader conversations in sport — more on that below.

Why now? What the WTA says

The WTA’s stated aim is straightforward: preserve the integrity of women’s professional tennis and keep competition fair for all players. That’s how the tour put it in their announcement, which ESPN reported on.

There’s also a timing angle. The move aligns the WTA more closely with the way some international bodies are approaching sex-classification rules ahead of the 2028 Los Angeles Olympics.

And it wasn’t done in a vacuum — the BBC reports the WTA board approved the update after consultation with members and said it reflects “evolving standards across women’s sport.”

How the SRY test works (and what it actually looks for)

If you’re not deep into genetics: SRY is a gene usually found on the Y chromosome that helps trigger male sex development. The new WTA test looks for that gene.

The BBC lays out the logistics: players can give a cheek swab, blood, or saliva sample for the test.

Important detail: this isn’t the same as the testosterone rules

The WTA’s previous policy — updated in 2024 — allowed transgender women to compete if they maintained testosterone below 2.5 nmol/L for two continuous years, per the BBC.

So this new approach shifts the focus from hormone levels to a genetic marker. That’s a constitutional change in how eligibility is determined, not just a tweak to enforcement.

Why people are upset — and why others back it

It’s not a surprise the reaction is loud and mixed. You’ve got people who see this as protecting fair competition in women’s sport, and you’ve got human rights and activist groups calling mandatory genetic screening problematic.

ESPN notes that human rights experts have criticized mandatory sex screening in sport, pointing to concerns about privacy, discrimination, and the dignity of athletes.

There’s another detail that complicates the optics: BBC reporting says there are currently no known transgender women playing on the WTA Tour today. So critics ask: who exactly is this aimed at and does it address a present problem or potential future one?

Practical and ethical concerns

• Privacy: genetic data is intimate. Players and advocates worry about storage, access, and secondary uses.
• Errors and edge cases: genetics can be messier than a binary checkbox — what happens in intersex conditions or atypical chromosomal setups?
• Stigma: a mandatory test tied to potential disciplinary action for refusal has serious reputational and career implications.

The WTA has said there will be further medical assessment when positive results occur, but the facts we have don’t lay out exactly how those assessments will work or how data will be handled. That uncertainty is part of the pushback.

Where this sits in the broader sporting landscape

This isn’t a rules experiment unique to tennis. ESPN points out that some other sports — like track and field, skiing, and boxing — already use similar approaches to sex classification.

And again: the WTA framed the change as bringing the tour closer to international eligibility standards, especially with an eye to the Olympics in 2028.

That matters because when one major sport alters its threshold for participation, others watch closely. Policy changes in high-profile sports can ripple — either encouraging similar moves or provoking legal and public-relations battles.

Immediate implications for players and tournaments

Here’s what actually changes on the ground, right away:

• Every current and incoming WTA player will have to submit a one-time sample.
• If the test is negative, nothing else changes career-wise.
• If it’s positive, the WTA says there’ll be further medical assessment before any eligibility ruling.
• Refusing to provide a sample could lead to disciplinary action under the new policy.

We don’t have published detail yet on how long players will have to comply, how samples will be stored, or who will run the testing labs. Those operational bits are going to be crucial and I’d expect players, unions, and lawyers to dig into them fast.

What this could mean long-term

If you’re thinking bigger-picture, there are a few realistic possibilities:

• Other governing bodies could adopt similar rules, especially if the WTA frames it as an accepted best practice.
• The legal and human-rights community may test the policy in court or through international sport arbitration — this stuff has a history of ending up in contentious legal fights.
• Practical fallout could include athletes delaying entries, seeking exemptions, or pushing for clearer protections around data and process.

At the same time, we should be honest about uncertainty. The available reporting doesn’t tell us whether any players will actually be directly affected right now, and the WTA says the move is about safeguarding women’s competition going forward.

FAQ — straightforward answers a fan would actually ask

Who has to take this test?

Every player on the WTA Tour must provide a one-time sample — cheek swab, blood, or saliva — to be tested for the SRY gene, according to BBC coverage.

What does a positive test mean?

The WTA says a positive result will trigger further medical assessment before any decision on eligibility. The policy doesn’t automatically ban someone outright; it starts a process.

Is this the same as testing testosterone?

No. The earlier WTA policy (updated in 2024) used a testosterone threshold — 2.5 nmol/L for two continuous years — but this new rule is a genetic screen for SRY.

Who reported this — is it official?

The policy has been reported by major outlets like ESPN and BBC Sport, and the WTA’s statement is the basis for those reports.

Are there any transgender women on the WTA right now who this applies to?

The BBC reports that there are currently no known transgender women competing on the WTA Tour. That’s part of why some observers are questioning the immediate necessity of the change.

Can a player refuse the test?

They can refuse, but the new rules require players to sign that refusal may lead to disciplinary action. The WTA’s statement, as covered by BBC, flags consequences for refusal.

What happens next

Expect a few threads to run in parallel:

• Players and player reps will want detail on logistics and data handling.
• Advocacy groups and human-rights lawyers will scrutinize privacy and discrimination implications.
• Other sports bodies and the IOC will watch closely — this could influence broader practice ahead of 2028.

For now, the rule is in place and the testing requirement begins this Tuesday. The stage is set for debate, legal questions, and — likely — more clarity on the practicalities as the WTA fills in the operational details.

One thing to remember

This is a big policy shift that changes the way eligibility is judged in women’s tennis: it moves from hormone thresholds to a genetic marker. The WTA says it’s about fairness and aligning with international standards; critics call for caution on privacy and human-rights grounds. Expect the next few months to be as much about process and protections as they are about principle.